Editor's Note Patients using GLP-1 receptor agonists (GLP-1 RAs) have a higher risk of food retention during esophagogastroduodenoscopy (EGD) when performed alone, but not when combined with a colonoscopy, according to a retrospective study from Cedars-Sinai Medical Center. MedPage Today reported the news October 1. The study included 70 patients…
Editor's Note Bariatric surgery significantly reduces the progression of chronic kidney disease (CKD) in patients with type 2 diabetes and obesity compared to those on GLP-1 diabetes medications, according to a study from Cleveland Clinic. Published in Annals of Surgery and detailed in a September 20 announcement from Cleveland Clinic,…
Editor's Note Research shows atrial fibrillation (Afib), a heart rhythm disorder, affects 10.5 million US adults—three times more than previously believed, HealthDay News reported September 12. The article focuses on a study from the University of California, San Francisco (UCSF), published in the Journal of the American College of Cardiology.…
Editor's Note A shuttered bariatric surgery center in Oklahoma last month is just one example of how the rise of Glucagon-like peptide-1 (GLP-1) agonists are reshaping health systems’ investments, Axios reported August 13. Rather than “massive hospital towers with cardiology clinics, dialysis beds and joint replacement centers,” the focus is…
Editor's Note For diabetic patients with obesity and chronic kidney disease (CKD), metabolic bariatric surgery could protect the kidneys better than therapy with glucagon-like peptide-1 receptor agonists (GLP-1RA), according to research published in the September issue of the Annals of Surgery. Conducted at a large US health system, the study…
Editor's Note Roux-en-Y gastric bypass (RYGB) reduces cardiovascular risk factors independent of calorie restriction and weight loss, according to a recent study published in JAMA Surgery. News-Medical.Net reported on the study July 4. Bariatric surgery, particularly RYGB, is more effective than non-surgical treatments for significant weight reduction and lowering cardiovascular…
Editor's Note Roux-en-Y gastric bypass surgery kept type 2 diabetes in remission for up to 15 years and maintained most of the weight loss for up to 20 years in a long-term study, according to a June 12 report in SciTech Daily. Presented the same day at The American Society…
Editor's Note Bariatric surgery provides longer-lasting, more effective weight loss than GLP-1 receptor agonists and lifestyle interventions, according to systematic reviews of medical literature from 2020 to 2024. Medical Xpress reported the news June 11. Presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2024 Annual Scientific Meeting,…
Editor's Note Preoperative use of GLP-1 receptor agonists (RA) medications such as Ozempic and Wegovy is safe, according to a study published in the June issue of the American Journal of Gastroenterology. Controversy has swirled around these drugs due to the risk of slowed stomach emptying increasing a patient’s odds…
Editor's Note Research shows perioperative weight loss does not consistently improve outcomes or OR times in patients undergoing primary bariatric procedures, including laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (RYGB). The findings were published in the June issue of the Journal of the American College of Surgeons. Using…